Egypt achieves record primary budget surplus of EGP 629bn despite sharp fall in Suez Canal revenues    Escalation in Gaza, West Bank as Israeli strikes continue amid mounting international criticism    Egypt recovers collection of ancient artefacts from Netherlands    Resumption of production at El Nasr marks strategic step towards localising automotive industry: El-Shimy    Egypt harvests 315,000 cubic metres of rainwater in Sinai as part of flash flood protection measures    Egypt, UNDP discuss outcomes of joint projects, future environmental cooperation    United Bank achieves EGP 1.51bn net profit in H1 2025, up 26.9% year-on-year    After Putin summit, Trump says peace deal is best way to end Ukraine war    Jordan condemns Israeli PM remarks on 'Greater Israel'    Egypt's Supreme Energy Council reviews power supply plans for 14 industrial projects    Egypt, Namibia explore closer pharmaceutical cooperation    Fitch Ratings: ASEAN Islamic finance set to surpass $1t by 2026-end    Renowned Egyptian novelist Sonallah Ibrahim dies at 88    Egypt's FM discusses Gaza, bilateral ties in calls with Saudi, South African counterparts    Egypt prepares to tackle seasonal air pollution in Nile Delta    Egyptian, Ugandan Presidents open business forum to boost trade    Al-Sisi says any party thinking Egypt will neglect water rights is 'completely mistaken'    Egypt's Sisi, Uganda's Museveni discuss boosting ties    Egypt's Sisi warns against unilateral Nile measures, reaffirms Egypt's water security stance    Egyptian pound closes high vs. USD on Tuesday – CBE    Egypt, Colombia discuss medical support for Palestinians injured in Gaza    Egypt, Huawei explore healthcare digital transformation cooperation    Egypt's Sisi, Sudan's Idris discuss strategic ties, stability    Egypt's govt. issues licensing controls for used cooking oil activities    Egypt to inaugurate Grand Egyptian Museum on 1 November    Egypt's Sisi: Egypt is gateway for aid to Gaza, not displacement    Greco-Roman rock-cut tombs unearthed in Egypt's Aswan    Egypt reveals heritage e-training portal    Sisi launches new support initiative for families of war, terrorism victims    Egypt expands e-ticketing to 110 heritage sites, adds self-service kiosks at Saqqara    Palm Hills Squash Open debuts with 48 international stars, $250,000 prize pool    On Sport to broadcast Pan Arab Golf Championship for Juniors and Ladies in Egypt    Golf Festival in Cairo to mark Arab Golf Federation's 50th anniversary    Germany among EU's priciest labour markets – official data    Paris Olympic gold '24 medals hit record value    A minute of silence for Egyptian sports    Russia says it's in sync with US, China, Pakistan on Taliban    It's a bit frustrating to draw at home: Real Madrid keeper after Villarreal game    Shoukry reviews with Guterres Egypt's efforts to achieve SDGs, promote human rights    Sudan says countries must cooperate on vaccines    Johnson & Johnson: Second shot boosts antibodies and protection against COVID-19    Egypt to tax bloggers, YouTubers    Egypt's FM asserts importance of stability in Libya, holding elections as scheduled    We mustn't lose touch: Muller after Bayern win in Bundesliga    Egypt records 36 new deaths from Covid-19, highest since mid June    Egypt sells $3 bln US-dollar dominated eurobonds    Gamal Hanafy's ceramic exhibition at Gezira Arts Centre is a must go    Italian Institute Director Davide Scalmani presents activities of the Cairo Institute for ITALIANA.IT platform    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



It's Time to Stop putting Profit ahead of Health
Published in The Egyptian Gazette on 14 - 03 - 2018


By: Dr. Mohamed Elmasry
For the past century the global pharmaceutical industry has increasingly placed money ahead of human well-being. It began by researching natural remedies discovered by our ancient ancestors, then synthesizing the active ingredients in their labs, patenting the process ... and now, making billions.
A recent report reveals that "Big Pharma fat cats have taken to extreme measures to ensure their drugs keep getting prescribed, namely bribing doctors in continuing prescriptions."
Among them, American drug manufacturer John Kapoor (founder and former CEO of Insys Therapeutics) was arrested in October 2017, charged with conspiring to bribe doctors to needlessly prescribe the powerful drug Fentanyl against the best interests of their patients.
Excessive prescription use and unprecedented street availability of opioids through organized crime have resulted in a skyrocketing overdose death rate in both the US and Canada. Opioids, notably Fentanyl, have created a new generation of addicts, many of whom abuse these drugs in combination with heroin, crack cocaine and other toxic substances.
The amoral behavior exhibited by Mr. Kapoor is chilling evidence of how aggressively Big Pharma executives are willing to push drug products purely for financial gain, despite fully knowing their devastating effects.
Acting United States Attorney William D. Weinreb stated: "In the midst of a nationwide opioid epidemic that has reached crisis proportions, Mr. Kapoor and his company stand accused of bribing doctors to overprescribe a potent opioid and committing fraud on insurance companies solely for profit."
Alarmingly, Kapoor and Insys Therapeutics are anything but an isolated case.
In the United States alone 1,630 drug manufacturing companies have made "incentive" payments totaling more than $3.5 billion to more than 681,000 doctors.
At the other end of the well-being scale, another U.S.-based Big Pharma player, Martin Shkreli (incarcerated in 2017 for securities fraud), became the media's "most hated man in America" when it was revealed in 2015 that his company, Turing Pharmaceuticals, had increased the price of a life-saving HIV drug by more than 5000% times.
Shkreli became notorious for mocking his critics and showing no remorse for actions which made a vital medication unaffordable for those who lives depended on it.
How did our society come to such a point where drug manufacturers can literally hold their customers hostage through sheer greed? Here is a brief history.
The for-profit pharmaceutical industry emerged during the mid-19th century, led by Germany's Merck Company. Originating as a pharmacy founded in 1668, in 1827 Heinrich Emanuel Merck began developing an industry for manufacturing and selling alkaloids.
In the US, Pfizer was founded in 1849 by German immigrants whose business expanded rapidly during the American Civil War as demand for painkillers soared.
Edward Robinson Squibb, a naval doctor during the Mexican-American war of 1846–1848 set up a laboratory in 1858; like Pfizer, his company supplied Union civil war armies.
The Bayer Company was founded in 1863 as a dye-manufacturer, but later moved into medicines. Around the turn of the 20th century, it commercialized Aspirin, one of the most profitable drugs in history.
In a 1950 interview, the year he appeared on the iconic cover of Time Magazine, George Merck said: "We try never to forget that medicine is for the people. It is not for the profits. The profits follow, and if we have remembered that, they have never failed to appear. The better we remember it, the larger they have been."
Ironically and tragically, Merck's vision has been virtually obliterated in the 21st century by the some of the biggest players in the pharmaceutical industry and we all suffer in some way from their ethical and moral failures.
So what can we do to stop the dangerous power of profit-driven Big Pharma and save our health? Here are some starting suggestions:
1. Deans of medical schools should integrate alterative medical care into their academic programs, so the next generation of medical professionals can reduce their reliance on prescribing synthetic drugs and adopt a more preventive healing approach that emphasizes diet, exercise, touch therapies such as massage, counseling, etc.
2. Governments should support and fund research on ancient natural and indigenous medicines used effectively for generations in Egypt, India, China, Africa, and among North American native peoples, and bring more of these practices into mainstream healthcare.
3. Governments and media should publicize lobbying campaigns by the pharmaceutical industry to ban alternative medicines.
4. Government-sponsored health insurance programs should cover medically recommended alternatives to synthetic drug usage.
5. Malpractice compensation maximums should be lowered to encourage qualified medical professionals to develop, test, apply and share more alternative treatments.
6. Non-invasive therapies should be encouraged to reduce the massive over-use of anti-depressant drugs, which reap billions in excess profit for major manufacturers.
7. Money incentives, bogus "research" grants, free big-ticket rewards (such as expense-paid trips), and other unearned "bribes" given to medical professionals by Big Pharma companies should be openly censured and reported in detail by governments and media.
8. Choosing medical school as a vocation for public good, rather than a fast-track to wealth alone, should be instilled into youth from middle school, or even earlier.
9. Long statutory limits on drug patents, which give originating companies excessive monopolies on supply, pricing, and profit-taking, should be lowered drastically, allowing more affordable generic drugs faster approval. Big Pharma lawyers should not be allowed to create barriers to the common good.
10. More and continuing research on the use and production of natural painkillers should be encouraged at both industry and government levels.
-----------------------------------
Dr. Mohamed Elmasry is Prof of Computer Engineering at the University of Waterloo and founding editor of TheCanadianCharger.com He can be reached at This email address is being protected from spambots. You need JavaScript enabled to view it.
---------------------------
In the United States alone 1,630 drug manufacturing companies have made "incentive" payments totaling more than $3.5 billion to more than 681,000 doctors.


Clic here to read the story from its source.